Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma, Hepatocellular × tivozanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Bile Duct Neoplasms 2 Vulvar Neoplasms 1 Sarcoma 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Hereditary Sensory and Autonomic Neuropathies 1 Gastrointestinal Neoplasms 1 Gallbladder Neoplasms 1 Disease 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Neuroendocrine 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Advanced Adult Hepatocellular Carcinoma 1

Interventions

Sorafenib 26 Nivolumab 21 pembrolizumab 15 Bevacizumab 15 lenvatinib 12 atezolizumab 10 Cyclophosphamide 9 Ipilimumab 8 durvalumab 6 camrelizumab 5 apatinib 5 Specimen Handling 5 Radiosurgery 5 tislelizumab 4 fludarabine 4 Immunotherapy, Adoptive 4 Fluorouracil 4 Doxorubicin 4 tremelimumab 3 toripalimab 3 sintilimab 3 regorafenib 3 cabozantinib 3 X-Rays 3 Magnetic Resonance Spectroscopy 3 Injections 3 Everolimus 3 Ethiodized Oil 3 Erlotinib Hydrochloride 3 tepotinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03970616 2023-07-12

DEDUCTIVE

AVEO Pharmaceuticals, Inc.

Phase 1/2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡